A microfluidic platform culturing two cell lines paralleled under in-vivo like fluidic microenvironment for testing the tumor targeting of nanoparticles

Wei, Juan; Cheng, Li-Chun; Li, Jingmin; Liu, Yuanchang; Yin, Shuqing; Xu, Bing; Wang, Dan; Lu, Huiyi; Liu, Chong

doi:10.1016/j.talanta.2019.120355

Cited by 6 publications

(4 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This model was used to demonstrate that tumour cells could be tracked using fluorescent nanoparticles, allowing live cell tracking and the surveillance of cellular proliferation and tumour growth. Notably, these nanoparticles were found to behave similarly in mouse models, suggesting that this platform represents a useful microphysiological system for modelling in vivo tumour growth [33].…”

Section: Tumour Growth/proliferationmentioning

confidence: 86%

Organ-on-a-Chip and Microfluidic Platforms for Oncology in the UK

Nolan

Pearce

Screen

et al. 2023

Cancers

View full text Add to dashboard Cite

Organ-on-chip systems are capable of replicating complex tissue structures and physiological phenomena. The fine control of biochemical and biomechanical cues within these microphysiological systems provides opportunities for cancer researchers to build complex models of the tumour microenvironment. Interest in applying organ chips to investigate mechanisms such as metastatsis and to test therapeutics has grown rapidly, and this review draws together the published research using these microfluidic platforms to study cancer. We focus on both in-house systems and commercial platforms being used in the UK for fundamental discovery science and therapeutics testing. We cover the wide variety of cancers being investigated, ranging from common carcinomas to rare sarcomas, as well as secondary cancers. We also cover the broad sweep of different matrix microenvironments, physiological mechanical stimuli and immunological effects being replicated in these models. We examine microfluidic models specifically, rather than organoids or complex tissue or cell co-cultures, which have been reviewed elsewhere. However, there is increasing interest in incorporating organoids, spheroids and other tissue cultures into microfluidic organ chips and this overlap is included. Our review includes a commentary on cancer organ-chip models being developed and used in the UK, including work conducted by members of the UK Organ-on-a-Chip Technologies Network. We conclude with a reflection on the likely future of this rapidly expanding field of oncological research.

show abstract

Section: Tumour Growth/proliferationmentioning

confidence: 86%

Organ-on-a-Chip and Microfluidic Platforms for Oncology in the UK

Nolan

Pearce

Screen

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…Finally, NPs can also be designed to target specific tumors based on their organ of origin. For instance, a microfluidic chip was designed to recapitulate the tumor microenvironment and assess the ability of NPs to specifically target cancer cells . Folic acid-cholesterol-chitosan NPs of 100 nm were tested on human lung adenocarcinoma (A549) and cervical cancer cells (Hela).…”

Section: Microfluidic Devicesmentioning

confidence: 99%

“…For instance, a microfluidic chip was designed to recapitulate the tumor microenvironment and assess the ability of NPs to specifically target cancer cells. 193 Folic acid-cholesterol-chitosan NPs of 100 nm were tested on human lung adenocarcinoma (A549) and cervical cancer cells (Hela). The fluorescence images showed the targeting ability of the studied NPs toward HeLa cells compared to A594 cells.…”

Section: Mucus Barriermentioning

confidence: 99%

Microfluidic Devices: A Tool for Nanoparticle Synthesis and Performance Evaluation

Gimondi,

Ferreira,

Reis

et al. 2023

ACS Nano

View full text Add to dashboard Cite

The use of nanoparticles (NPs) in nanomedicine holds great promise for the treatment of diseases for which conventional therapies present serious limitations. Additionally, NPs can drastically improve early diagnosis and follow-up of many disorders. However, to harness their full capabilities, they must be precisely designed, produced, and tested in relevant models. Microfluidic systems can simulate dynamic fluid flows, gradients, specific microenvironments, and multiorgan complexes, providing an efficient and cost-effective approach for both NPs synthesis and screening. Microfluidic technologies allow for the synthesis of NPs under controlled conditions, enhancing batch-to-batch reproducibility. Moreover, due to the versatility of microfluidic devices, it is possible to generate and customize endless platforms for rapid and efficient in vitro and in vivo screening of NPs’ performance. Indeed, microfluidic devices show great potential as advanced systems for small organism manipulation and immobilization. In this review, first we summarize the major microfluidic platforms that allow for controlled NPs synthesis. Next, we will discuss the most innovative microfluidic platforms that enable mimicking in vitro environments as well as give insights into organism-on-a-chip and their promising application for NPs screening. We conclude this review with a critical assessment of the current challenges and possible future directions of microfluidic systems in NPs synthesis and screening to impact the field of nanomedicine.

show abstract

“…These microfluidic devices are also advantageous as some of them can mimic physiological conditions. Traditional preclinical studies are heavily relied on a high number of animal models due to the lack of poor recapitulation in cell culture dishes [206]. Third, the EPR effect requires a better understanding since tumors grow quickly and blood vessels are leaky in mice models resulting in efficient EPR effect.…”

Section: Challengesmentioning

confidence: 99%

Carrier-free nanodrugs for safe and effective cancer treatment

Karaosmanoglu

Zhou

Shi

et al. 2021

Journal of Controlled Release

117

View full text Add to dashboard Cite

Clinical applications of many anti-cancer drugs are restricted due to their hydrophobic nature, requiring use of harmful organic solvents for administration, and poor selectivity and pharmacokinetics resulting in off-target toxicity and inefficient therapies. A wide variety of carrier-based nanoparticles have been developed to tackle these issues, but such strategies often fail to encapsulate drug efficiently and require significant amounts of inorganic and/or organic nanocarriers which may cause toxicity problems in the long term. Preparation of nanoformulations for the delivery of water insoluble drugs without using carriers is thus desired, 2 requiring elegantly designed strategies for products with high quality, stability and performance. These strategies include simple self-assembly or involving chemical modifications via coupling drugs together or conjugating them with various functional molecules such as lipids, carbohydrates and photosensitizers. During nanodrugs synthesis, insertion of redox-responsive linkers and tumor targeting ligands endows them with additional characteristics like on-target delivery, and conjugation with immunotherapeutic reagents enhances immune response alongside therapeutic efficacy. This review aims to summarize the methods of making carrier-free nanodrugs from hydrophobic drug molecules, evaluating their performance, and discussing the advantages, challenges, and future development of these strategies.

show abstract

A microfluidic platform culturing two cell lines paralleled under in-vivo like fluidic microenvironment for testing the tumor targeting of nanoparticles

Cited by 6 publications

References 45 publications

Organ-on-a-Chip and Microfluidic Platforms for Oncology in the UK

Organ-on-a-Chip and Microfluidic Platforms for Oncology in the UK

Microfluidic Devices: A Tool for Nanoparticle Synthesis and Performance Evaluation

Carrier-free nanodrugs for safe and effective cancer treatment

Contact Info

Product

Resources

About